Advertisement
Screener

SOLIGENIX, INC. (SNGX) Gain (Loss) on Derivative Instruments, Net, Pretax

2.8 / 5 stars · 68/120 Roast Me

SOLIGENIX, INC. Gain (Loss) on Derivative Instruments, Net, Pretax

SOLIGENIX, INC. (SNGX) reported Gain (Loss) on Derivative Instruments, Net, Pretax of -$1.54 million for the 12-month period ending 2016-12-31, per its 10-K filed 2018-03-15.

Discontinued › Income Statement › Other Income

us-gaap:GainLossOnDerivativeInstrumentsNetPretax · last filed 2018-03-15

  • SOLIGENIX, INC. gain (loss) on derivative instruments, net, pretax for the quarter ending 2016-12-31 was -$2.65M.
  • SOLIGENIX, INC. gain (loss) on derivative instruments, net, pretax for the quarter ending 2016-09-30 was -$176.29K, a 104.36% decline year-over-year.
  • SOLIGENIX, INC. gain (loss) on derivative instruments, net, pretax for the quarter ending 2016-06-30 was $525.33K.
  • SOLIGENIX, INC. gain (loss) on derivative instruments, net, pretax for the quarter ending 2016-03-31 was $760.16K.
  • SOLIGENIX, INC. gain (loss) on derivative instruments, net, pretax for fiscal 2016 was -$1.54M.
  • SOLIGENIX, INC. gain (loss) on derivative instruments, net, pretax for fiscal 2014 was $3.44M.
  • SOLIGENIX, INC. gain (loss) on derivative instruments, net, pretax for fiscal 2013 was -$3.65M.
Period endGain (Loss) on Derivative Instruments, Net, Pretax 3 monthGain (Loss) on Derivative Instruments, Net, Pretax 6 monthGain (Loss) on Derivative Instruments, Net, Pretax 9 monthGain (Loss) on Derivative Instruments, Net, Pretax 12 monthGain (Loss) on Derivative Instruments, Net, Pretax 12 month as first filed
2016-12-31-$2.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15
-$2.83M
derived: sum of 2 quarters · filed 2018-03-15
-$2.30M
derived: sum of 3 quarters · filed 2018-03-15
-$1.54M
10-K · filed 2018-03-15
$1.54M
10-K · filed 2017-03-27
2016-09-30-$176.29K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06
$349.04K
derived: sum of 2 quarters · filed 2017-11-06
$1.11M
10-Q · filed 2017-11-06
2016-06-30$525.33K
10-Q · filed 2017-08-11
$1.29M
10-Q · filed 2017-08-11
2016-03-31$760.16K
10-Q · filed 2017-05-11
2015-09-30$4.05M
10-Q · filed 2016-11-10
2014-12-31$3.44M
10-K · filed 2016-03-24
2014-06-30$746.99K
10-Q · filed 2014-08-11
-$995.10K
10-Q · filed 2014-08-11
$699.55K
derived: sum of 3 quarters · filed 2015-03-25
-$4.00M
derived: sum of 4 quarters · filed 2015-03-25
2014-03-31-$1.74M
10-Q · filed 2014-05-12
-$47.44K
derived: sum of 2 quarters · filed 2015-03-25
-$4.75M
derived: sum of 3 quarters · filed 2015-03-25
-$5.40M
derived: sum of 4 quarters · filed 2015-03-25
2013-12-31$1.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-25
-$3.01M
derived: sum of 2 quarters · filed 2015-03-25
-$3.65M
derived: sum of 3 quarters · filed 2015-03-25
-$3.65M
10-K · filed 2015-03-25
2013-09-30-$4.70M
10-Q · filed 2013-11-12
-$5.35M
derived: sum of 2 quarters · filed 2014-08-11
-$5.35M
10-Q · filed 2013-11-12
2013-06-30-$649.58K
10-Q · filed 2014-08-11
-$649.58K
10-Q · filed 2014-08-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
Imunon, Inc. (IMNN)United States$0.008B-0.56
EXICURE, INC. (XCUR)United States$0.008B-1.54
Traws Pharma, Inc. (TRAW)United States$0.009B-0.58
Alzamend Neuro, Inc. (ALZN)United States$0.009B
Ensysce Biosciences, Inc. (ENSC)United States$0.008B-0.37
InMed Pharmaceuticals Inc. (INM)$0.008B-0.65
Apimeds Pharmaceuticals US, Inc. (APUS)United States$0.008B
FibroBiologics, Inc. (FBLG)United States$0.009B-0.27
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B
Acurx Pharmaceuticals, Inc. (ACXP)United States$0.007B-0.97